OBT Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
News Jan 12, 2012
Dr Begley, who was the Vice President and Global Head of Hematology and Oncology Research at Amgen, will take on a key role in helping shape and execute OBT’s clinical and corporate strategy as it advances its pipeline of oncology antibody-based drugs into clinical development.
C. Glenn Begley has over 10 years of experience in leading the strategy and co-ordination of Oncology Research at Amgen, and brings extensive knowledge and expertise to OBT at an exciting phase in the company’s development.
As Vice-President and Global Head of Hematology and Oncology at Amgen, Dr Begley was responsible for advancing 24 molecules into clinical development, including several human monoclonal antibodies and antibody drug conjugates.
Before joining Amgen in 2002, Dr Begley also gained over 20 years of clinical experience in medical oncology and haematology.
He has held several academic positions including Executive Director at the Western Australian Institute of Medical Research, and Senior Principal Research Fellow and Professor of Medicine at the University of Melbourne at Walter and Eliza Hall Institute of Medical Research.
He is also Board Certified in Australia as a Medical Oncologist and Haematologist (F.R.A.C.P.), and Laboratory Haematologist (F.R.C.P.A., Australia; F.R.C.Path, United Kingdom) and holds a PhD in cellular and molecular biology.
Dr Begley commented, “I am excited by this unique opportunity to join a high-calibre team at a rapidly advancing biotech company with an impressive pipeline of preclinical cancer programs and network of collaborators / licensing partners. I look forward to working with the company’s senior management team and board of directors as OBT realizes its goal of transforming the targeted treatment of cancer by successfully driving its pipeline of antibody-based therapeutics into the clinic.”
Dr Christian Rohlff, CEO of OBT, commented, “I am delighted to welcome Glenn to OBT. His wealth of relevant clinical and commercial expertise in the oncology and antibody field will be instrumental in helping OBT to transition into a successful clinical development organization as the company works to enhance the future treatment prospects for cancer patients with no treatment.”
Today’s announcement follows OBT’s recent collaboration with Seattle Genetics, Inc. for the development of antibody drug conjugates (ADCs) for cancer, highlighting OBT’s growing recognition in the ADC field.
A new study has identified a drug that potentially could make a common type of immunotherapy for cancer even more effective. The study in laboratory mice found that the drug dasatinib, which is FDA-approved to treat certain types of leukemia, greatly enhances responses to a form of immunotherapy that is used against a wide range of other cancers.